Erlotinib and pancreatic adenocarcinoma: uncertainty and hope
- PMID: 21630121
- DOI: 10.1245/s10434-011-1809-x
Erlotinib and pancreatic adenocarcinoma: uncertainty and hope
Comment on
-
Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer.Ann Surg Oncol. 2011 Apr;18(4):1122-9. doi: 10.1245/s10434-010-1401-9. Epub 2010 Nov 23. Ann Surg Oncol. 2011. PMID: 21104328 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
